Malignant neuroendocrine tumors
ICD-10 Codes (0)
No codes found matching your search
Updates & Changes
FY 2026 Updates
New Codes (2)
Revised Codes (2)
Deleted Codes
No codes deleted in this range for FY 2026
Historical Changes
- •FY 2025: Routine maintenance updates with minor terminology clarifications
- •FY 2024: Enhanced specificity requirements for certain code ranges
- •FY 2023: Updated documentation guidelines for improved clarity
Upcoming Changes
- •Proposed updates pending review by Coordination and Maintenance Committee
- •Under consideration: Enhanced digital health integration codes
Implementation Guidance
- •Review all FY 2026 updates for C7A-C7A codes before implementation
- •Always verify the most current codes in the ICD-10-CM manual
- •Ensure clinical documentation supports the selected diagnosis codes
- +3 more guidance items...
Range Overview
The ICD-10 code range C7A-C7A pertains to malignant neuroendocrine tumors. These codes are used to classify and document various types of malignant neuroendocrine tumors, including carcinoid tumors, Merkel cell carcinomas, and neuroendocrine carcinomas. The codes provide a detailed classification system for these conditions, facilitating accurate documentation, reporting, and statistical tracking. They are used by medical coders, healthcare providers, researchers, and public health officials.
Key Usage Points:
- •Always verify the type of malignant neuroendocrine tumor from the medical record before coding.
- •Use additional codes to specify any associated conditions or complications.
- •Remember that the C7A-C7A codes only apply to malignant neuroendocrine tumors, not benign or unspecified ones.
- •For metastatic tumors, use additional codes to specify the primary site of the tumor.
- •Always check the latest ICD-10 updates and changes for any revisions or additions to the C7A-C7A code range.
Coding Guidelines
When to Use:
- ✓When a patient is diagnosed with a malignant neuroendocrine tumor.
- ✓When a patient has a history of malignant neuroendocrine tumor and is receiving follow-up care.
- ✓When a patient is being treated for complications associated with a malignant neuroendocrine tumor.
- ✓When coding cause of death in a patient with a malignant neuroendocrine tumor.
When NOT to Use:
- ✗When the tumor is benign or unspecified.
- ✗When the patient has a neuroendocrine tumor, but it is not malignant.
- ✗When the patient is at risk for developing a malignant neuroendocrine tumor, but has not been diagnosed with one.
- ✗When the patient has a history of malignant neuroendocrine tumor, but it is not relevant to the current episode of care.
Code Exclusions
Always verify the malignancy status of the tumor from the medical record before coding.
Documentation Requirements
When documenting malignant neuroendocrine tumors, it is important to provide detailed and accurate information. This includes the type of tumor, its location, its malignancy status, any associated conditions or complications, and the patient's treatment plan.
Clinical Information:
- •Type of malignant neuroendocrine tumor
- •Location of the tumor
- •Malignancy status of the tumor
- •Associated conditions or complications
- •Treatment plan
Supporting Evidence:
- •Pathology reports
- •Imaging studies
- •Operative reports
- •Clinical notes
Good Documentation Example:
Patient diagnosed with a malignant carcinoid tumor of the small intestine. Pathology report confirms malignancy. Patient undergoing chemotherapy.
Poor Documentation Example:
Patient has a tumor in the small intestine.
Common Documentation Errors:
- ⚠Not specifying the type of neuroendocrine tumor
- ⚠Not documenting the malignancy status of the tumor
- ⚠Not including associated conditions or complications
- ⚠Not providing a detailed treatment plan
Range Statistics
Coding Complexity
Coding malignant neuroendocrine tumors can be complex due to the need to accurately determine the type and location of the tumor, verify its malignancy status, and code any associated conditions or complications. Additionally, coders must stay current with any updates or changes to the C7A-C7A code range.
Key Factors:
- ▸Determining the type of malignant neuroendocrine tumor
- ▸Identifying the location of the tumor
- ▸Verifying the malignancy status of the tumor
- ▸Coding any associated conditions or complications
- ▸Keeping up with any updates or changes to the C7A-C7A code range
Specialty Focus
The C7A-C7A codes are primarily used by oncologists, pathologists, and surgeons. They are also used by other specialists and healthcare providers involved in the care of patients with malignant neuroendocrine tumors.
Primary Specialties:
Clinical Scenarios:
- • Patient diagnosed with a malignant carcinoid tumor of the small intestine.
- • Patient undergoing surgery for a malignant Merkel cell carcinoma.
- • Patient receiving chemotherapy for a malignant neuroendocrine carcinoma.
- • Patient with a history of malignant neuroendocrine tumor receiving follow-up care.
Resources & References
There are many resources available to help with coding malignant neuroendocrine tumors. These include the official ICD-10 coding guidelines, clinical reference sources, and educational materials.
Official Guidelines:
- ICD-10-CM Official Guidelines for Coding and Reporting
- American Hospital Association's Coding Clinic
- National Cancer Institute's SEER Coding and Staging Manual
Clinical References:
- American Cancer Society's Guide to Cancer
- National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology
Educational Materials:
- American Health Information Management Association's ICD-10-CM Coding Handbook
- American Academy of Professional Coders' ICD-10-CM Training Manual
Frequently Asked Questions
How do I code a malignant neuroendocrine tumor with metastasis?
First, code the malignant neuroendocrine tumor using the appropriate C7A-C7A code. Then, use an additional code to specify the site of the metastasis.